Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants

Tango Therapeutics, Inc.

Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.
Annual base salary of $550,000; one-time sign-on bonus of $275,000 (clawback if leaves before Feb 27, 2024).
Equity grants: stock options for 487,500 shares and RSUs for 81,250 shares, with time-based vesting.
Target annual cash incentive of 45% of base salary; severance includes 12 months salary and COBRA coverage.
Crystal previously CMO at C4 Therapeutics and clinical program leader at Novartis.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adam Crystal

President, Research & Development

TNGX · Tango Therapeutics, Inc.

Effective: 2023-02-27
Filed: February 28, 2023, 6:59 PM ET

On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Adam Crystal was appointed as President, Research & Development at Tango Therapeutics, Inc..

Action: appointed
Role: President, Research & Development

Exact text from the filing

On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.

View on SEC.gov

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-052289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.